NCT00514475View on ClinicalTrials.gov

Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

90Y-ibritumomab tiuxetan (Zevalin)

90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.

Trial Locations (1)

0310

Arne Kolstad, Oslo

All Listed Sponsors

lead

Oslo University Hospital

OTHER

NCT00514475 - Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter